Assessment of the Impact of Oral Intervention With Cetylpyridinium Chloride to Decrease SARS-CoV-2 Viral Load in Patients With COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-03

Study Completion Date

2021-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pilot, randomized and controlled clinical trial for the evaluation of the decrease in the viral load of SARS-CoV-2 in the oropharynx in patients with COVID-19 through the use of mouthwash containing cetylpyridinium chloride (CPC) (0.07%) in mouthwash.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Double-blind, Randomized, Parallel, Placebo-controlled Clinical Study to Evaluate the Viral Load of SARS-CoV-2 (COVID-19) in the Oral Cavity of SARS-CoV-2 Positive Subjects After the Use of a Mouthwash Containing Cetylpyridinium Chloride 0,07%.

NCT04757818

SARS-CoV-2 Infection

COMPLETED NA

Evaluation of SARS-COV-2 Viral Load of Covid-19 Patients After Rinsing With Oral Antimicrobial Mouthwashes

NCT04902976

Covid19

COMPLETED NA

Pilot Study to Evaluate Effect of CHX0.12/CPC 0.05 of SARS-CoV-2 Viral Load in COVID-19 Patients

NCT04563689

Covid19

COMPLETED NA

Efficacy of Mouthwashes in Reducing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load in the Saliva

NCT04723446

Covid19 Coronavirus

COMPLETED NA

Evaluation of the Efficacy of Mouth Rinses With Commercial Mouthwashes to Decrease Viral Load in Saliva in COVID-19 Patients

NCT05543603

covid19

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of the clinical trial is to determine the short-term efficacy of cetylpyridinium chloride (CPC) mouthwashes to assess changes in the threshold cycle value of the analysis of the SARS-CoV-2 oropharyngeal saliva sample, in patients diagnosed with COVID-19 and with symptomatology compatible with the disease. A randomized double-blind pilot clinical trial (evaluator and patients) will be developed in patients with a diagnosis of COVID-19 and symptoms of the disease. The experimental group will perform a single rinse with a mouthwash containing Cetylpyridinium Chloride (CPC) while the placebo group will perform the same rinse, but with a harmless liquid that will act as a placebo. The study will be carried out in the Zaragoza III Health Sector, with patients belonging to the Zaragoza II Health Sector, collaborating with the "Seminario" health center and the Lozano Blesa Clinical University Hospital (HCULB). This project will be carried out in accordance with the CONSORT guidelines for clinical trials.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 SARS-CoV-2 Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Accepting an alpha risk of 0.05 and a beta risk of 0.2 in a bilateral contrast, 40 subjects in the first group and 40 in the second were required to detect a difference equal to or greater than 5 units. The common standard deviation is assumed to be 10 (12). A loss to follow-up rate of 20% has been estimated.

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Randomized double-blind pilot clinical trial (evaluator and patients) in patients with a diagnosis of COVID-19 and symptoms of the disease.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cetylpyridinium Chloride (CPC) 0,07%

patients who rinse with cetylpyiridinium chloride 0,07% mouthwash for 60 seconds

Group Type EXPERIMENTAL

ORAL INTERVENTION WITH CETYLPYRIDINIUM CHLORIDE

Intervention Type OTHER

one mouthwash containing cetylpyridinium chloride (0.07%) for 60 seconds

Placebo: Distilled water with the same flavor and coloring as the product to be evaluated

patients who rinse with distilled water mouthwash for 60 seconds

Group Type PLACEBO_COMPARATOR

PLACEBO

Intervention Type OTHER

one mouthwash containing distilled (placebo) water for 60 seconds

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ORAL INTERVENTION WITH CETYLPYRIDINIUM CHLORIDE

one mouthwash containing cetylpyridinium chloride (0.07%) for 60 seconds

Intervention Type OTHER

PLACEBO

one mouthwash containing distilled (placebo) water for 60 seconds

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Outpatients older than 18 years and younger than 80 years.
* Patients with a medical indication for a diagnostic test for active infection to SARS-CoV-2
* Patients who present mild symptoms typical of COVID-19 and who have less than three days of evolution
* Patients who have cognitive and motor skills to perform mouthwash correctly.
* Patients who understand and speak Spanish
* Patients who freely give their consent to participate in the study, after a correct understanding of its objectives and procedures.

Exclusion Criteria

* Patients with hospitalization criteria (moderate or severe symptoms)
* Vulnerable populations such as pregnant, lactating,
* Patients with recent medical diagnosis (≤ 1 month) of pneumonia
* Patients with hyposialia
* Patients with consumption of oral antiseptics (in the form of mouthwash containing CPC, povidone iodine rinses, alcohol mouthwash and essential oils) and toothpastes with CPC during the last month.
* Patients with cognitive impairment

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes